HOME >> BIOLOGY >> NEWS
Blocking neurodegeneration by radiation and bone marrow transfer prevents inherited glaucoma in mice

Bar Harbor, Maine In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked the development of glaucoma, by preventing neurodegeneration.

Glaucomas are among the most common neurodegenerative diseases, and a leading cause of blindness in the United States. Many patients with glaucoma have high intraocular pressure (IOP), long believed to be a cause of the degeneration of the optic nerve and nerve cells in the retina that leads to vision loss. The standard treatment for glaucoma is reducing the intraocular pressure by medication or surgery.

However, researchers have also observed that some patients with elevated IOP do not develop optic nerve and retinal damage, while others do incur damage despite relatively normal IOP. "It's increasingly clear," says Dr. Simon W.M. John, leader of the Jackson Laboratory research team and a Howard Hughes Medical Institute Investigator, "that multiple mechanisms are at work in this disease."

John and researchers elsewhere have identified several genes associated with glaucomas. They have also developed inherited mouse glaucoma models that reliably develop glaucoma in mid-life. One of these models is the DBA/2J mouse.

The Jackson research team treated 5- to 8-week-old DBA/2J mice with a single, high dose of gamma radiation, together with bone marrow transfer.

When they examined the mice at 12-14 months--an age at which most DBA/2J mice have advanced glaucoma--the researchers were amazed to find that the vast majority of mice did not have glaucoma. There was no detectable loss of the retinal ganglion cells, which typically degenerate in glaucoma.

"It was very surprising and we had to be very careful," John said. "We repeated the experiment two more times with the same results."

The research p
'"/>

Contact: Joyce Peterson
joyce@jax.org
207-288-6058
Jackson Laboratory
10-Mar-2005


Page: 1 2

Related biology news :

1. Blocking beta1-integrin to treat cancer
2. Blocking a premature aging syndrome with anticancer drugs
3. Blocking blood vessels provides new option for large group of advanced lung cancer patients
4. Blocking COX-1 slows tumor growth in mice
5. Blocking PLK-1 to beat bladder cancer
6. Blocking cell signaling can stymie viral infections, study shows
7. Blocking cell suicide switch fails to stop prion damage in mouse brains
8. Early environmental exposure may accelerate age-related neurodegeneration
9. Enhanced environment restores memory in mice with neurodegeneration
10. Salk and Stanford teams join forces to reveal two paths of neurodegeneration
11. Transcription factor proteins role in cell death, neurodegeneration and schizophrenia

Post Your Comments:
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: